Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Fluorescein. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 8/20 | 0.89 |
| ▸ | MAPT | P10636 | 4/20 | 0.89 |
| ▸ | MEN1 | O00255 | 4/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.89 |
| ▸ | HTT | P42858 | 2/20 | 0.89 |
| ▸ | HPGD | P15428 | 2/20 | 0.89 |
| ▸ | RECQL | P46063 | 2/20 | 0.89 |
| ▸ | BLM | P54132 | 2/20 | 0.89 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.89 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorescein SCHEMBL11135740 | 1.00 | FTO (0.89) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL106710 | 1.00 | FTO (0.89) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL4630179 | 0.99 | FTO (0.87) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL20740618 | 0.95 | FTO (0.85) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL29371199 | 0.94 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL29388667 | 0.94 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL30272223 | 0.94 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL16533 | 0.94 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL3645090 | 0.94 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL11132218 | 0.94 | FTO (0.79) | FTOMAPTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2676140-A2 | SUBSTRATES AND METHODS FOR STAINING LIVE CELLS | Life Technologies Corporation (US) | 2013-12-25 | — | — | EP | claimed |
| US-20130323770-A1 | SUBSTRATES AND METHODS FOR STAINING LIVE STEM CELLS | Life Technologies Corporation (US) | 2013-12-05 | — | — | US | claimed |
| WO-2012112609-A2 | SUBSTRATES AND METHODS FOR STAINING LIVE CELLS | Life Technologies Corporation (US) | 2012-08-23 | — | — | WO | claimed |
| CN-101384729-A | Solid phase sequencing | AMERSHAM BIOSCIENCES CORP (US) | 2009-03-11 | — | — | CN | claimed |
| US-5830666-A | USING A FLUORESCEIN DERIVATIVE PHOSPHATE ESTER | AISIN SEIKI KABUSHIKI KAISHA (JP) | 1998-11-03 | — | — | US | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12385902-B2 | Methods for generating and screening compartmentalised peptide libraries | UNIVERSITY OF SOUTHAMPTON (GB) | 2025-08-12 | — | — | US | disclosed |
| US-20250195438-A1 | LYOPHILIZED MESENCHYMAL STEM CELL DERIVED SECRETOME AND USES THEREOF | COMBANGIO, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12186430-B2 | Lyophilized mesenchymal stem cell derived secretome and uses thereof | COMBANGIO, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118759190-A | Chemiluminescent immunoassay CLIA kit for measuring TPS and method for measuring TPS | 泰州泽成生物技术有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-12012632-B2 | Methods for obtaining and correcting biological sequence information | CYGNUS BIOSCIENCES (BEIJING) CO., LTD (CN) | 2024-06-18 | — | — | US | disclosed |
| US-20240166641-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-05-23 | — | — | US | disclosed |
| EP-0424465-A4 | PREPARATION AND USE OF FLUORESCENT BENZOTHIAZOLE DERIVATIVES | — | 1991-07-03 | — | — | EP | disclosed |
| EP-0424465-A1 | PREPARATION AND USE OF FLUORESCENT BENZOTHIAZOLE DERIVATIVES. | JBL SCIENT INC (US) | 1991-05-02 | — | — | EP | disclosed |
| WO-1990000618-A1 | PREPARATION AND USE OF FLUORESCENT BENZOTHIAZOLE DERIVATIVES | JBL SCIENTIFIC, INC. (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0070832-A4 | MICROENCAPSULATED FLUORESCER COMPOSITION, TEST KIT AND SYSTEM FOR IMMUNOASSAY. | ELECTRO NUCLEONICS (US) | 1983-06-17 | — | — | EP | disclosed |
| EP-0070832-A1 | MICROENCAPSULATED FLUORESCER COMPOSITION, TEST KIT AND SYSTEM FOR IMMUNOASSAY | ELECTRO-NUCLEONICS, INC. (US) | 1983-02-09 | — | — | EP | disclosed |
| US-4372745-A | QUALITATIVE AND QUANTITATIVE ANALYSIS | ELECTRO-NUCLEONICS, INC. (US) | 1983-02-08 | — | — | US | disclosed |
| WO-1982002772-A1 | MICROENCAPSULATED FLUORESCER COMPOSITION,TEST KIT AND SYSTEM FOR IMMUNOASSAY | ELECTRO NUCLEONICS (US) | 1982-08-19 | — | — | WO | disclosed |
| WO-1981001883-A1 | CHEMICAL LUMINESCENCE AMPLIFICATION SUBSTRATE SYSTEM FOR IMMUNOCHEMISTRY | ELECTRO NUCLEONICS (US) | 1981-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | FTO 1625/4885MAPT 2945/4885MEN1 4405/4885 |
| US-20240166641-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | FTO 4764/4885MAPT 3935/4885MEN1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.